Stahl Stephen M
CNS Spectr. 2017 Feb;22(1):1-4. doi: 10.1017/S109285291600095X.
Pharmacogenomic testing can be integrated into modern mental health practices to help select psychotropic drugs for individuals who have failed first-line evidence-based treatments. This can be done by the process of "equipoise"-namely, balancing the weight of all available evidence. That evidence now includes not only diagnosis-specific treatment guidelines and "personalized" patient information, such as an individual's specific symptom profile, past response to medications, side effects, family history, and patient preference, but also "precision medicine," which incorporates the ever-expanding base of pharmacogenomic evidence for how an individual's own biomarkers alter the odds for that individual's treatment response or treatment intolerance.
药物基因组学检测可以整合到现代心理健康实践中，以帮助为那些一线循证治疗失败的个体选择精神药物。这可以通过“ equipoise”过程来完成，即平衡所有现有证据的权重。现在，该证据不仅包括特定诊断的治疗指南和“个性化”患者信息，例如个体的特定症状概况、过去对药物的反应、副作用、家族史和患者偏好，还包括“精准医学”，它纳入了不断扩大的药物基因组学证据基础，即个体自身的生物标志物如何改变个体治疗反应或治疗不耐受的几率。
